For research use only. Not for therapeutic Use.
Tusamitamab ravtansine（Cat No.:I042126）is an investigational antibody-drug conjugate (ADC) designed to target and treat solid tumors, particularly those expressing the tumor-associated antigen TROP2. The therapy combines an anti-TROP2 monoclonal antibody with a cytotoxic agent, allowing for precise delivery of the chemotherapy drug directly to cancer cells. By targeting TROP2, Tusamitamab ravtansine aims to reduce the impact on healthy cells while maximizing the destruction of cancerous tissue. It is being studied in clinical trials for its effectiveness in treating various cancers, including non-small cell lung cancer and other solid tumors.
| CAS Number | 2254086-60-5 |
| Purity | ≥95% |
